Metabolic mapping of the rat brain after subanesthetic doses of ketamine: Potential relevance to schizophrenia

Brain Research

Volumn 787, Issue 2, 1998, Pages 181-190

  Duncan, Gary E ^a   Moy, Sheryl S ^a   Knapp, Darin J ^a   Mueller, Robert A ^a   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Cingulate cortex; Hippocampus; Ketamine; Limbic system; NMDA; Prefrontal cortex; Schizophrenia

Indexed keywords

DEOXYGLUCOSE; KETAMINE; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN MAPPING; BRAIN METABOLISM; BRAIN REGION; CONTROLLED STUDY; HIPPOCAMPUS; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC CORTEX; MALE; NEUROANATOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIMETABOLITES; AUTORADIOGRAPHY; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; CEREBRAL CORTEX; DEOXYGLUCOSE; EXCITATORY AMINO ACID ANTAGONISTS; IMMUNOHISTOCHEMISTRY; KETAMINE; MALE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 0032559875     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)01390-5     Document Type: Article

References (71)

1. Andreasen N.C., Rezai K., Alliger R.et al. Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;943-958.
2. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br. J. Pharmacol. 79:1983;565-575.
3. + transport in canine brain. Stroke. 12:1981;726-730.
4. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of sernyl. Compr. Psychiatry. 2:1961;269-280.
5. Bustos G., Abarca J., Forrey M.I., Gysling K., Bradbery C.W., Roth R.H. Regulation excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies. Brain Res. 585:1992;105-115.
6. Byrd L.D., Standish L.J., Howell L.L. Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur. J. Pharmacol. 144:1987;331-341.
7. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;72-276.
8. Cartwright P.D., Pingel S.M. Midazolam and diazepam in ketamine anesthesia. Anaesthesia. 59:1984;439-442.
9. Cohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl) lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium: II. Symbolic and sequential thinking. Arch. Gen. Psychiatry. 6:1962;79-85.
10. Cohen M.L., Chan S.L., Bhargave H.N., Trevor A.J. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem. Pharmacol. 23:1974;1647-1652.
11. Coppel D.L., Bovill J.G., Dundee J.W. The taming of ketamine. Anesthesia. 28:1973;293-296.
12. Corssen G., Domino E.F. Dissociative anesthesia: further pharmacologic studies and first clinical experience with phencyclidine derivative Cl-581. Anesth. Analg. 45:1966;29-40.
13. Crosby G., Crane A.M., Sokoloff L. Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiology. 56:1982;437-443.
14. Davies B.M., Beech H.R. The effect of 1-arylcyclohexylamine (sernyl) on twelve normal volunteers. J. Ment. Sci. 106:1960;912-924.
15. Deutsch S.I., Mastropaolo J., Schwartx B.L., Rosse R., Morihisa J.M. A glutamate hypothesis of schizophrenia. Clin. Neuropharmacol. 12:1989;1-13.
16. Domino E.F., Chodoff P., Corssen G. Pharmacological effects of CI-581. A new dissociative anesthetic in man. Clin. Pharmacol. Ther. 6:1965;279-291.
17. Dragunow M., Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Meth. 29:1989;261-265.
18. Dragunow M., Faull R.L.M. MK-801 induces c-Fos protein in thalamic and neocotical neurons of rat brain. Neurosci. Lett. 111:1990;39-45.
19. G.E. Duncan, High resolution autoradiographic imaging of brain activity patterns with 2-deoxyglucose: regional topographic and cellular analysis, in: F. Gonzalez-Lima, Th. Finkenstadt, H. Scheich (Eds.), Advances in Metabolic Mapping Techniques for Brain Imaging of Behavioral and Learning Functions, NATO Advanced Science Institute Series, Vol. 68, 1992, pp. 152-173.
20. G.E. Duncan, W.E. Stumpf, High resolution autoradiographic imaging of brain activity patterns with radiolabled 2-deoxyglucose, in: P.M. Conn (Ed.), Methods in Neurosciences, Vol. 3, Academic Press, New York, 1990, pp. 50-64.
21. 3H-2-deoxyglucose. Brain Res. 401:1987;43-49.
22. Duncan G.E., Johnson K.B., Breese G.R. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. Neurosci. 13:1993;3932-3943.
23. Duncan G.E., Knapp D.J., Johnson K.B., Breese G.R. Functional Classification of antidepressants based upon antagonism of swim stress-induced Fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 277:1996;1076-1089.
24. Dundee J.W., Lilburn J.K. Ketamine-lorazepam: attenuation of the psychic sequelae of ketamine by lorazepam. Anaesthesia. 37:1977;312-314.
25. Farber N.B., Price M.T., Labruyere J., Nemnich J., St. Peter H., Wozniak D.F., Olney J.W. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol. Psychiatry. 34:1993;119-121.
26. Ferrer-Allado T., Brechner V.L., Dymond A., Cozen H., Crandall P. Ketamine induced electroconvulsive phenomena in human limbic and thalamic regions. Anesthesiology. 38:1973;333-344.
27. Fratta W., Casu M., Balestrieri A., Loviselli A., Biggio G., Gessa G.L. Failure of ketamine to interact with opiate receptors. Eur. J. Pharmacol. 61:1980;389-391.
28. Frith C. The role of the prefrontal cortex I self-consciousness: the case of auditory hallucinations. Biol. Sci. 351:1996;1505-1512.
29. Gao X., Shirakawa O., Du F., Tamminga C.A. Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol. 241:1993;7-15.
30. Gur R.C., Gur R.E. Hypofrontality in schizophrenia: RIP. Lancet. 345:1995;1383-1384.
31. Gur R.E., Mozley P.D., Resnick S.M., Mozley L.H., Shtasel D.L., Gallacher F., Arnold S.E., Karp J.S., Alavi A., Reivich M.et al. Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch. Gen. Psychiatry. 52:1995;657-667.
32. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
33. Jones E.G. Cortical development and the neuropathology of schizophrenia. Ciba Foundation Symposium. 193:1995;277-295.
34. Kadekaro M., Vance W.H., Terrell M.L., Gary H. Jr., Eisenberg H.M., Sokoloff L. Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat. Proc. Natl. Acad. Sci. USA. 84:1997;5492-5495.
35. Kayama Y., Iwama K. The EEG evoked potentials and single-unit activity during ketamine anesthesia in cata. Anesthesiology. 36:1972;316-328.
36. Krystal J.H., Karper L., Pseibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry. 51:1994;199-214.
37. Kurumaji A., Nehls D.G., Park C.K., McCulloch J. Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 496:1989;268-284.
38. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
39. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 6:1995;869-872.
40. Liu J., Moghaddam B. Regulation of glutamate efflux by excitatory amino acid receptors: evidence for tonic inhibitory and phasic excitatory regulation. J. Pharmacol. Exp. Ther. 274:1995;1209-1215.
41. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., Kelley R. Study of a new schizophrenomimetic drug - sernyl. Arch. Neurol. Psych. 81:1959;363-369.
42. Malhortra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 14:1996;301-307.
43. Manohar S., Maxwell D., Winters W.D. Development of EEG seizure activity during and after chronic ketamine administration in the rat. Neuropharmacology. 11:1972;819-826.
44. Mata M., Fink D.J., Gainer H., Smith C.B., Davidsen L., Savaki H., Schwartz W.J., Sokoloff L. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J. Neurochem. 34:1980;213-215.
45. McCown T.J., Duncan G.E., Breese G.R. Neuroanatomical characterization of inferior collicular seizure genesis: 2-deoxyglucose and stimulation mapping. Brain Res. 567:1991;25-32.
46. McCown T.J., Duncan G.E., Johnson K.B., Breese G.R. Metabolic and functional mapping of the neural network subserving inferior collicular seizure generalization. Brain Res. 701:1995;117-128.
47. Moghaddam B., Adams B., Verman A., Daly D. Activation of glutamaterigic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17:1997;2921-2927.
48. Morgan J.L., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 14:1991;421-451.
49. Mori K., Kawamata M., Mitani H., Yamazaki Y., Fujita M. A neurophysiologic study of ketamine anesthesia in the cat. Anesthesiology. 35:1971;373-383.
50. Nakao S., Adachi T., Murakawa M., Shinomura T., Kurata J., Schichino T., Shibata M., Tooyama I., Kimura H., Mori K. Halothane and diazepam inhibit ketamine-induced c-Fos expression in the rat cingulate cortex. Anesthesiology. 85:1996;874-882.
51. Nakao S., Arai T., Mori K., Yasuhara O., Tooyama I., Kimura H. High-dose ketamine does not induce c-Fos protein expression in rat hippocampus. Neurosci. Lett. 151:1993;33-36.
52. Nakki R., Nickolenko J., Chang J., Sagar S.M., Sharp F.R. Haloperidol prevents ketamine and phencyclidine induced hsp70 protein expression but not microglial activation. Exper. Neurol. 137:1996;234-241.
53. Nelson S.R., Howard R.B., Cross R.S., Samson F. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology. 52:1980;330-334.
54. Norman R.M., Malla A.K., Morrison-Stewart S.L., Helmes E., Williamson P.C., Thomas J., Cortese L. Neuropsychological correlates of syndromes in schizophrenia. Br. J. Psychiatry. 170:1997;134-139.
55. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
56. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and protection. Science. 254:1991;1515-1518.
57. N. Oye, O. Hustveit, E.R. Moberg, O. Pausen, L.A. Skoglund, The chiral forms of ketamine as probes for NMDA receptor function in humans, in: T. Kameyama, T. Nebeshima, E.F. Domino (Eds.), NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior, NPP Books, Ann Arbor, MI, 1991, pp. 381-389.
58. Raja S.N., Guyenet P.G. Actions of phencyclidine on synaptic transmission in the hippocampus. Brain Res. 236:1982;289-304.
59. 14C) 2-deoxyglucose uptake in the caudal cerebellum of the rat during motor/sensory cortex stimulation. J. Comp. Neurol. 284:1989;621-636.
60. Sharp F.R., Butman M., Wang S., Kiostanaho J., Grahm S., Burger P., Sagar S.M., Longo F.M. Haloperidol and rimcazole prevent induction of HSP72 protein and hsp70 mRNA in neurons injured by phencyclidine and MK-801. J. Neurosci. Res. 33:1992;605-616.
61. Sharp F.R., Jasper P., Hall J., Nobel L., Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann. Neurol. 30:1991;801-809.
62. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
63. Siegel B.V., Buchsbaum B.S., Bunney W.E.et al. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am. J. Psychiatry. 150:1993;1325-1356.
64. Sinclair J.G., Tien A.F. Neuronal responses to ketamine administered microiontophoretically or intraperitoneally in the rat. Gen. Pharmacol. 10:1979;51-55.
65. Smith D.J., Azzaro A.J., Zaldivar S.B., Palmer S., Lee H.S. Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology. 120:1981;391-396.
66. Smith D.J., Pekoe G.M., Martin L.L., Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 26:1980;789-795.
67. Thomson A.M., West D.C., Lodge D. An N-methyl-aspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature. 313:1985;479-481.
68. Weinberger D.R., Berman K.F., Zec R.F. Physiology dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow (rCBF) evidence. Arch. Gen. Psychiatry. 43:1986;114-124.
69. White P.F., Way W.L., Trevor A.J. Ketamine - its pharmacology and therapeutic uses. Anesthesiology. 56:1982;119-136.
70. Winters W.D., Ferrer-Allado T., Guzman-Flores C., Alcaraz M. The cataleptic state induced by ketamine: a review of the neuropharmacology of anesthesia. Neuropharmacology. 11:1972;303-315.
71. 3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes. J. Neurochem. 50:1988;274-281.